NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading STTK? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The current thesis is cautious, as the company is loss-making and faces near-term risks, but it operates in a sector with potential tailwinds.
The market appears to have low expectations for STTK, as indicated by a significant premium compared to peers. However, the valuation is considered unjustified given the company's current performance and the expectations gap.
Fundamentals are likely to remain weak in the near term, especially with a high probability of missing earnings expectations. Recent changes in company momentum show some improvement, but overall performance still lags behind industry peers.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX. If these companies continue to perform well, STTK may benefit, but any negative guidance from them could lead to further challenges.
Over the next 1 to 3 years, STTK's outlook is uncertain, with risks outweighing potential rewards at this stage. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings will provide insight into financial health and operational progress. This is a key moment for investors.
Confirms one read:Earnings report shows revenue growth exceeding 10% year over year.
Confirms the other:Earnings report shows revenue growth below 0% year over year.
Why it matters: Starting the Phase 2 trial on schedule shows progress in drug development. It signals confidence in SL-325's potential for Crohn's disease treatment.
Confirms:The Phase 2 clinical trial of SL-325 in Crohn's disease begins in Q3 2026 as planned.
Disproves:The Phase 2 trial does not start in Q3 2026 or is delayed.
Why it matters: If the healthcare sector's revenue growth speeds up, it could benefit Shattuck Labs.
Confirms:Healthcare sector revenue growth exceeds 10% year over year.
Disproves:Healthcare sector revenue growth remains below 5% year over year.
Why it matters: Details about the debt will show financial health and future funding plans.
Confirms one read:Debt issuance closes well with good terms and strong investor interest.
Confirms the other:Debt issuance faces strong investor resistance or bad terms.
Why it matters: Maintaining cash flow is crucial for funding operations into 2029. Investors need to see how well this strategy works.
Confirms:They completed stock offerings that raised at least $20 million.
Disproves:Stock offerings do not raise the expected funds or are delayed a lot.
Why it matters: Recent debt details can affect financial health and how investors feel.
Confirms one read:New terms from the debt issuance show good conditions.
Confirms the other:Debt issuance terms show bad conditions or high interest rates.
Why it matters: Updates on cash flow will show if the company can fund operations through 2029.
Confirms:Management says cash flow is positive after the stock offerings.
Disproves:Management says cash flow is negative after the stock offerings.
Why it matters: Updates on cash flow after the stock offering will show how well Shattuck can fund its operations. This is key for long-term growth.
Confirms one read:Shattuck has cash flow to support operations until 2029 after the stock offering.
Confirms the other:Cash flow updates show a shorter time frame than expected. This raises funding concerns.
